Cardiology – Medxy AI

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

By MedXY 01/02/2026

Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombotic risk profile, offering a viable strategy for individualized care.

Cardiology news

Timing Matters: Platelet Reactivity Predicts Early Events While Clinical Risk Governs Long-Term Outcomes Post-PCI

By MedXY 12/30/2025

Analysis of the PTRG-DES registry shows that platelet reactivity drives early ischemic risk post-PCI, while clinical risk factors (TRS2P) determine long-term prognosis, suggesting a need for temporally tailored secondary prevention strategies.

Cardiology news

Refining Risk: Clinical and Angiographic Predictors of Postprocedural Troponin Elevation in Elective PCI

By MedXY 12/30/2025

A comprehensive analysis of over 10,000 patients identifies key risk factors for post-PCI troponin increase, highlighting the protective role of intravascular imaging and the prognostic impact of different myocardial infarction definitions.

Cardiology Critical Care news

Beyond Chronological Age: How Frailty Dictates Survival and Functional Recovery After Out-of-Hospital Cardiac Arrest

By MedXY 12/28/2025

A secondary analysis of the TTM2 trial reveals that frailty is a potent predictor of mortality and poor neurological outcomes after out-of-hospital cardiac arrest, with severely frail patients facing a 35-fold higher risk of poor functional recovery.

Cardiology Internal Medicine news

Redefining Iron Deficiency in Heart Failure: Why TSAT and Serum Iron Outperform Ferritin for Prognosis

By MedXY 12/26/2025

Recent large-scale studies, including HEART-FID and major national registries, demonstrate that transferrin saturation (TSAT) and serum iron levels are more accurate predictors of functional capacity and mortality in heart failure than traditional ferritin-based definitions.

Cardiology Internal Medicine news

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF

By MedXY 12/26/2025

A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit excess abdominal adiposity, necessitating a shift in clinical assessment.

Cardiology news

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood pressure and advanced age, emphasizing the need for vigilant clinical monitoring.

Cardiology news

Coramitug Significantly Reduces NT-proBNP in Transthyretin Amyloid Cardiomyopathy: Phase 2 Trial Results

By MedXY 12/25/2025

A Phase 2 randomized trial shows that coramitug, a monoclonal antibody targeting misfolded transthyretin, significantly reduced NT-proBNP levels by 48% in patients with ATTR-CM. While functional outcomes remained stable over 52 weeks, the results suggest a breakthrough in active amyloid clearance.

Cardiology Internal Medicine news

N-Palmitoyl Glutamine: A Novel Molecular Link Between Exercise, Mitochondrial Efficiency, and Human Longevity

By MedXY 12/25/2025

A groundbreaking study identifies N-palmitoyl glutamine (NPG) as a key molecular transducer of cardiorespiratory fitness. NPG correlates with VO2max, increases with exercise training, predicts lower mortality, and directly enhances mitochondrial function, offering a potential therapeutic target for cardiometabolic health.

Cardiology news

Beyond Vagal Tone: Genetic Predisposition and Physical Fitness Drive Profound Bradycardia in Elite Athletes

By MedXY 12/24/2025

A comprehensive study of elite endurance athletes reveals that resting bradycardia (≤40 bpm) is common and driven by both fitness and a lower polygenic risk score for heart rate. These findings suggest that genetics may predispose individuals to athletic success and sinus node remodeling.

Cardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

By MedXY 12/24/2025

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.

Cardiology Emergency Medicine news

High-Sensitivity Cardiac Troponin Risk Stratification Safely Accelerates ED Discharge and Improves 1-Year Outcomes

By MedXY 12/24/2025

A secondary analysis of the HiSTORIC trial reveals that using high-sensitivity cardiac troponin for risk stratification significantly reduces ED length of stay and increases safe discharge rates for low- and intermediate-risk patients, with improved 1-year safety outcomes.

Cardiology news

Long-Term Silicon Exposure Fails to Predict Coronary Artery Disease Severity or Systemic Inflammation

By MedXY 12/24/2025

A pilot study evaluating hair silicon as a long-term mineral marker found no significant association between silicon concentrations and coronary artery disease (CAD) severity or inflammatory markers, suggesting silicon may be metabolically neutral in advanced atherosclerosis.

Cardiology Internal Medicine news

Aggressive LDL-C Lowering Mitigates Neoatherosclerosis Risk: Insights from the CONNECT Trial

By MedXY 12/24/2025

This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of aggressive lipid management in secondary prevention.

Cardiology news

Obstructive Coronary Artery Disease Does Not Diminish Long-Term Health Status or Clinical Efficacy After TAVR: 3-Year Insights from SCOPE I

By MedXY 12/21/2025

A post hoc analysis of the SCOPE I trial reveals that obstructive coronary artery disease (CAD) does not significantly impact 3-year survival or patient-reported health status following TAVR, questioning the routine necessity of periprocedural PCI in this population.

Cardiology news

Prophylactic Pacemakers After TAVR: Low Pacing Burden Raises Questions on Routine Use

By MedXY 12/17/2025

One-fourth of TAVR patients receive prophylactic pacemakers, but most have minimal pacing needs at 30 days.

Cardiology news

PROMOTE Study Validates Algorithm for Conduction Disturbance Management After TAVR

By MedXY 12/17/2025

A prospective multicenter study confirms that a prespecified algorithm for conduction disturbance management after TAVR is safe, with low sudden cardiac death risk but persistent high pacemaker rates.

Cardiology news

Safety and Efficacy of the Trilogy Transcatheter Aortic Valve for High-Risk Native Aortic Regurgitation: Insights from the ALIGN-AR Studies

By MedXY 11/28/2025

The ALIGN-AR studies demonstrate that transcatheter aortic valve implantation using the Trilogy valve is a safe and effective treatment for symptomatic native moderate-to-severe or severe aortic regurgitation in patients at high surgical risk, showing favorable valve function and clinical outcomes up to two years.

AI Cardiology news

AI-Augmented Screening Triples Detection Yield of Transthyretin Cardiac Amyloidosis in a Multisite Real-World Trial

By MedXY 11/18/2025

An AI-driven screening program (ATTRACTnet) applied to ECG, echocardiography, demographics and orthopedic history substantially increased case detection of transthyretin cardiac amyloidosis (ATTR‑CM) and led to rapid treatment initiation in a target population.

Cardiology news Pediatrics

Innovations in Atrial Septal Defect Closure: Comparing Bioresorbable and Metallic Occluders

By MedXY 10/24/2025

This article reviews a landmark randomized trial demonstrating that bioresorbable occluders are noninferior to metallic ones in ASD closure, with implications for improved patient outcomes and device management.